Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06355934 · ClinicalTrials.gov registry record
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
A clinical trial of ATTR Amyloidosis, sponsored by AstraZeneca.
- Recruiting
- Registry status
- 52,121
- Enrollment target
- 20
- Study locations
NCT06355934: Recruiting study of ATTR Amyloidosis, sponsored by AstraZeneca.
NCT06355934 is a study of ATTR Amyloidosis that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 52,121 participants. The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06355934, a study of ATTR Amyloidosis, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- 52,121 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.
Primary Outcome
Annualized events rate for: Overall outpatient visits
Conditions Studied
Interventions
- OTHER no intervention
Study Locations (20)
Other
- Research Site - Beijing
- Research Site - Changsha
- Research Site - Chengdu
- Research Site - Guangzhou
- Research Site - Wuhan
- Research Site - Horsens
- Research Site - Berlin
- Research Site - Tokyo
- Research Site - Lisbon
- Research Site - Porto
- Research Site - A Coruña
- Research Site - Barcelona
- Research Site - Bilbao
- Research Site - El Palmar
- Research Site - Huelva
- Research Site - Las Palmas de Gran Canaria
- Research Site - Madrid
- Research Site - Majadahonda
Minnesota
- Research Site - Eden Prairie
Alberta
- Research Site - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52,121 participants |
| Start Date | 2023-08-21 |
| Est. Completion | 2026-09-30 |
What NCT06355934 shows while recruiting
NCT06355934 is an observational study that tracks outcomes without assigning an intervention. Its 52,121 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with ATTR Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which no intervention is the first listed.
NCT06355934 names 20 study sites across 3 states, led by Other, Minnesota, Alberta.
Frequently Asked Questions
What is clinical trial NCT06355934 about?
NCT06355934 is a clinical study titled "OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis". The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropa...
What is the current status of trial NCT06355934?
This trial is currently recruiting. The enrollment target is 52,121 participants. The study started on 2023-08-21. Estimated completion is 2026-09-30.
What conditions does trial NCT06355934 study?
This clinical trial studies the following conditions: ATTR Amyloidosis.
What interventions are being tested in trial NCT06355934?
The interventions under investigation include: no intervention (OTHER).
Who is sponsoring clinical trial NCT06355934?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06355934 being conducted?
This trial has 20 study locations across Minnesota, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ATTR Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05975671 · 52,500 participants · NA
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
- NCT07224243 · 54,000 participants · NA
Impact of Intraoperative Oxygenation Practices on Patient Outcomes
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
- NCT01885299 · 50,000 participants
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI